US Allows More Vyvanse Production to Address ADHD Drug Shortages

US drug authorities are allowing 24% more production of Vyvanse, an ADHD drug from Takeda Pharmaceutical Co. and generic rivals, to address treatment shortages that have dragged on for the past two years.

Medicines for attention-deficit/hyperactivity disorder have been in short supply since the summer of 2022, when labor issues curtailed availability of Adderall — a cornerstone of treatment — amid increasing demand. Patients turned to alternative therapies, leading to knock-on shortages of drugs including Vyvanse.

The Drug Enforcement Administration increased Vyvanse’s production limit for 2024 at the behest of the Food and Drug Administration, the DEA said in ...